Not yet recruiting
CM336 Plus Daratumumab and Lenalidomide in Transplant-Ineligible Newly Diagnosed Multiple Myeloma
NCT07830485· Phase 2· Institute of Hematology & Blood Diseases Hospital, China· Source
Contact: Gang An, MD, PhD
Recruiting
CM336 Plus Isa-VR in Newly Diagnosed Primary Plasma Cell Leukemia
NCT07652905· Phase 2· Institute of Hematology & Blood Diseases Hospital, China· Source
Contact: Gang An, PhD & MD
Recruiting
CM336 Plus Isatuximab for Newly Diagnosed Multiple Myeloma With Renal Impairment
NCT07585760· Phase 2· Institute of Hematology & Blood Diseases Hospital, China· Source
Contact: Gang An, PhD & MD
Not yet recruiting
A Study of BL-M11D1 in Patients With Relapsed/Refractory Myelodysplastic Syndromes
NCT07591168· Phase 1/2· Sichuan Baili Pharmaceutical Co., Ltd.· Source
Contact: Zhijian Xiao
Not yet recruiting
Sonrotoclax and BCMA Bispecific Antibody in Newly Diagnosed Systemic AL Amyloidosis Based on t(11;14) Genetic Stratification
NCT07687004· Phase 1/2· Institute of Hematology & Blood Diseases Hospital, China· Source
Contact: Gang An, MD, PhD
Not yet recruiting
BCMA/GPRC5D Trispecific Antibody Treatment for Newly Diagnosed Amyloidosis (AL-004)
NCT07751471· Phase 2· Institute of Hematology & Blood Diseases Hospital, China· Source
Contact: Gang an, MD
Recruiting
MRD-Guided BCMA/CD3 Bispecific Antibody Treatment After Stem Cell Transplant for Newly Diagnosed Multiple Myeloma
NCT07409454· Phase 2· Institute of Hematology & Blood Diseases Hospital, China· Source
Contact: Gang An
Recruiting
A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A
NCT07416604· Phase 3· Hoffmann-La Roche· Source
Recruiting
Mosunetuzumab and Zeprumetostat in Treating Patients With Follicular Lymphoma
NCT07555470· Phase 2· Institute of Hematology & Blood Diseases Hospital, China· Source
Contact: Yuting Yan
Recruiting
A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia
NCT07255872· Phase 2/3· Sichuan Baili Pharmaceutical Co., Ltd.· Source
Contact: Jianxiang Wang
Recruiting
Safety of KN057 Prophylaxis in Patients With Haemophilia A or B
NCT07545395· Phase 3· Suzhou Alphamab Co., Ltd.· Source
Contact: Renchi Yang, Doctor
Recruiting
Zanubrutinib, Obinutuzumab Combined With Lenalidomide (ZGR) for the Treatment of Untreated Follicular Lymphoma
NCT07299149· Phase 2· Institute of Hematology & Blood Diseases Hospital, China· Source
Contact: Yuting Yan
Recruiting
Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma
NCT07261163· Phase 2· Institute of Hematology & Blood Diseases Hospital, China· Source
Contact: Yuting Yan
Recruiting
BCMA/CD3 Bispecific Antibody Treatment for Newly Diagnosed Amyloidosis
NCT07151690· Phase 2· Institute of Hematology & Blood Diseases Hospital, China· Source
Contact: Gang An, PhD&MD
Recruiting
Post-transplantation Maintenance Therapy With Cidabenamide in Patients With Intermediate/High-risk AML
NCT07304232· Phase 2· Institute of Hematology & Blood Diseases Hospital, China· Source
Contact: Jiang Erlie, doctor
Recruiting
ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Ultra-High-Risk Multiple Myeloma
NCT07106710· Phase 2· Institute of Hematology & Blood Diseases Hospital, China· Source
Contact: Gang An
Recruiting
MRD-Adaptive Guided Immunotherapy With CAR-T for Transplant-Ineligible Patients With Multiple Myeloma
NCT07106736· Phase 2· Institute of Hematology & Blood Diseases Hospital, China· Source
Contact: Gang An
Recruiting
A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma
NCT07106671· Phase 2· Institute of Hematology & Blood Diseases Hospital, China· Source
Contact: Gang An
Recruiting
ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Primary Plasma Cell Leukemia
NCT07106684· Phase 2· Institute of Hematology & Blood Diseases Hospital, China· Source
Contact: Gang An
Recruiting
A Study of CT0596 in Plasma Cell Leukemia
NCT06988059· Early phase 1· Institute of Hematology & Blood Diseases Hospital, China· Source
Contact: Gang An, PhD
Recruiting
Aponermin-Based Bridging Therapy Prior to CAR-T Infusion in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease
NCT06793475· Institute of Hematology & Blood Diseases Hospital, China· Source
Contact: Gang An, PhD&MD
Recruiting
Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma
NCT06830031· Phase 1· Shanghai Exuma Biotechnology Ltd.· Source
Contact: Jianfeng Huo, Bachelor
Recruiting
BCMA CAR-T for Dynamic High-risk Multiple Myeloma
NCT06880393· Phase 2· Institute of Hematology & Blood Diseases Hospital, China· Source
Contact: Gang An, PhD&MD
Recruiting
BCMA CAR-T Versus ASCT in Transplant-eligible Patients With Multiple Myeloma
NCT06793449· Phase 2· Institute of Hematology & Blood Diseases Hospital, China· Source
Contact: Gang An, PhD&MD
Recruiting
BCMA/CD3 BsAb in the Treatment of High-risk Smoldering Multiple Myeloma
NCT06745687· Institute of Hematology & Blood Diseases Hospital, China· Source
Contact: Gang An, MD&PhD
Recruiting
Long-term Follow-up Registry Study of Equecabtagene Autoleucel Injection
NCT07028970· Nanjing IASO Biotechnology Co., Ltd.· Source
Contact: Dehui Zou
Active, not recruiting
Obinutuzumab, Zanubrutinib, and Lenalidomide Followed Short-Cycle of Obinutuzumab and Cytarabine in Newly Diagnosed Mantle Cell Lymphoma
NCT06504199· Phase 2· Institute of Hematology & Blood Diseases Hospital, China· Source
Recruiting
A Study of GLB-001 in Patients With Myeloid Malignancies
NCT06378437· Phase 1· Hangzhou GluBio Pharmaceutical Co., Ltd.· Source
Contact: Lei Zhang, MD
Active, not recruiting
Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B Without Inhibitors
NCT06569108· Phase 3· Suzhou Alphamab Co., Ltd.· Source
Active, not recruiting
A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)
NCT06464991· Phase 3· Nanjing IASO Biotechnology Co., Ltd.· Source
Active, not recruiting
Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B With Inhibitors
NCT06312475· Phase 3· Suzhou Alphamab Co., Ltd.· Source
Recruiting
A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms
NCT06150157· Phase 1· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study of GNC-035 in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematological Malignancies
NCT05944978· Phase 1/2· Sichuan Baili Pharmaceutical Co., Ltd.· Source
Recruiting
A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd)-Based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With Primary Plasma Cell Leukemia
NCT05979363· Phase 2· Institute of Hematology & Blood Diseases Hospital, China· Source
Contact: Gang An, PhD&MD
Recruiting
A Study of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
NCT05924750· Phase 1· Sichuan Baili Pharmaceutical Co., Ltd.· Source
Contact: Yali Zhang
Active, not recruiting
A Study of VRD-based Regimen Combined With CART-ASCT-CART2 Treatment in Patients With Primary Plasma Cell Leukemia
NCT05870917· Phase 2· Institute of Hematology & Blood Diseases Hospital, China· Source
Active, not recruiting
A Study of VRd-based Regimen Combined With CART-ASCT-CART2 Treatment in NDMM Patients With P53 Abnormalities
NCT05850286· Phase 2· Institute of Hematology & Blood Diseases Hospital, China· Source
Active, not recruiting
A Study of VRd-based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With New-diagnosed Multiple Myeloma
NCT05860036· Phase 2· Institute of Hematology & Blood Diseases Hospital, China· Source
Recruiting
Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Follicular Lymphoma in Real World Study
NCT05846763· Institute of Hematology & Blood Diseases Hospital, China· Source
Contact: Rui Lyu
Active, not recruiting
A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma
NCT04712097· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL
NCT04521231· Phase 1/2· Amgen· Source
Active, not recruiting
Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation
NCT03173248· Phase 3· Institut de Recherches Internationales Servier· Source